NICE fast-tracks GSK's Tafinlar
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has recommended GlaxoSmithKline's melanoma drug Tafinlar (dabrafenib) in final draft guidance, having skipped the consultation process in order to get the drug on the market faster. The move is in sharp contrast to Tafinlar's previous reimbursement experience in Germany, where the drug was deemed to have no additional benefit over competitors.